PERTH, Australia – Digital health company ResApp’s mobile app is 91% to 100% accurate in distinguishing adult patients with COPD, asthma or pneumonia from subjects with no discernable respiratory disease, a recent study has found. The app was 100% accurate in distinguishing patients with an upper respiratory tract infection. The results are part of an ongoing study at Joondalup Health Campus and Wesley Hospital. Using ResApp, a patient coughs or breathes into a smartphone’s microphone and a machine-learning algorithm diagnoses conditions, including COPD, pneumonia, asthma and upper respiratory tract infections.
You are here: / / Study of adults with COPD, pneumonia, asthma shows ResApp’s accuracy is high